Literature DB >> 25527013

Novel induction therapies for pleural mesothelioma.

Laura Donahoe1, John Cho1, Marc de Perrot2.   

Abstract

Malignant mesothelioma is becoming increasingly common, and rates of diagnosis are expected to continue to increase in the coming years because of the extensive use of asbestos in industrialized countries and the long time interval between exposure and onset of disease. Although much research has been done on the optimal treatment for this disease, the overall prognosis remains grim. The main components of therapy are surgery, chemotherapy, and radiation therapy, but there is controversy in the literature about the optimal inclusion and sequencing of these treatments, as each has unique risk profiles. We have developed a new Surgery for Mesothelioma After Radiation Therapy protocol consisting of induction-accelerated hemithoracic radiation followed by extrapleural pneumonectomy. The rationale behind this protocol is to maximize both the tumoricidal and immunogenic potential of the radiotherapy while minimizing the radiation toxicity to the ipsilateral lung. Our initial trial demonstrated the feasibility of this approach and has shown encouraging results in patients with epithelial histology. In this article, we reviewed the current literature on induction chemotherapy for mesothelioma as well as described the Surgery for Mesothelioma After Radiation Therapy protocol and upcoming studies of novel induction therapies for mesothelioma.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  extrapleural pneumonectomy; hemithoracic radiation; mesothelioma; neoadjuvant therapy; pleuropneumonectomy; surgery

Mesh:

Year:  2014        PMID: 25527013     DOI: 10.1053/j.semtcvs.2014.08.003

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  5 in total

1.  The Role of Neoadjuvant Chemotherapy in Patients With Resectable Malignant Pleural Mesothelioma-An Institutional and National Analysis.

Authors:  Soraya L Voigt; Vignesh Raman; Oliver K Jawitz; Muath Bishawi; Chi-Fu Jeffrey Yang; Betty C Tong; Thomas A D'Amico; David H Harpole
Journal:  J Natl Cancer Inst       Date:  2020-11-01       Impact factor: 13.506

2.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

Review 3.  Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

Authors:  Luciano Mutti; Tobias Peikert; Bruce W S Robinson; Arnaud Scherpereel; Anne S Tsao; Marc de Perrot; Gavitt A Woodard; David M Jablons; Jacinta Wiens; Fred R Hirsch; Haining Yang; Michele Carbone; Anish Thomas; Raffit Hassan
Journal:  J Thorac Oncol       Date:  2018-09       Impact factor: 15.609

4.  P2X7 targeting inhibits growth of human mesothelioma.

Authors:  Francesca Amoroso; Erica Salaro; Simonetta Falzoni; Paola Chiozzi; Anna Lisa Giuliani; Giorgio Cavallesco; Pio Maniscalco; Andrea Puozzo; Ilaria Bononi; Fernanda Martini; Mauro Tognon; Francesco Di Virgilio
Journal:  Oncotarget       Date:  2016-08-02

5.  A Redox-Silent Analogue of Tocotrienol May Break the Homeostasis of Proteasomes in Human Malignant Mesothelioma Cells by Inhibiting STAT3 and NRF1.

Authors:  Kyota Ishii; Momoka Fusegi; Tatsuki Mori; Kosuke Teshima; Nanako Ninomiya; Kakeru Kohno; Ayami Sato; Tatsuya Ishida; Yuichi Miyakoshi; Tomohiro Yano
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.